Table 3.
Differences in absolute changes in IgG-TrimericS antibody levels from the booster dose up to three months assessed by univariate and multivariate linear regression (p-value).
| p-Value | |||
|---|---|---|---|
| Univariate | Multivariable According To Abdominal Obesity | Multivariable According to BMI Class | |
| Sex | 0.7120 | 0.5955 | 0.5656 |
| Age | 0.3000 | 0.4485 | 0.5412 |
| IgG-TrimetricS antibody level at booster dose | 0.0675 | 0.0855 | 0.0526 |
| Prior SARS-CoV-2-infection | <0.0001 | <0.0001 | <0.0001 |
| Abdominal obesity | 0.1053 | 0.1092 | - |
| Interaction with prior SARS-CoV-2-infection * Abdominal obesity | 0.0163 | - | |
| BMI classes | 0.0803 | - | 0.0821 |
| Interaction with prior SARS-CoV-2-infection * BMI classes | - | 0.4176 | |
| Smoking status | 0.0925 | 0.3785 | 0.2968 |
| Hypertension | 0.0062 | 0.0020 | 0.0063 |
| Diabetes mellitus | 0.5878 | ||
| Cardiovascular diseases | 0.7262 | ||
| Dyslipidemia | 0.5087 | ||
| Cancer | 0.3900 | ||
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); abdominal obesity (waist circumference ≥ 102 cm for men, ≥88 cm for women); Body Mass Index (BMI).